<DOC>
	<DOCNO>NCT02672917</DOCNO>
	<brief_summary>Phase I Safety Tolerability Study Subjects Pancreatic Cancer Other CA19-9 Positive Malignancies .</brief_summary>
	<brief_title>Study HuMab-5B1 ( MVT-5873 ) Subjects With Pancreatic Cancer Other Cancer Antigen 19-9 ( CA19-9 ) Positive Malignancies</brief_title>
	<detailed_description>Open label , multi-center , nonrandomized , dose escalation trial MVT-5873 evaluate safety determine MTD recommend phase II dose MVT-5873 monotherapy ( Group A ) combination standard care chemotherapy ( Group B ) subject pancreatic CA19-9 positive malignancy . Both group utilize conventional 3+3 study design identify MTD recommend phase II dose ( RP2D ) . follow determination MTD , 10 additional subject treat RP2D group . The pharmacokinetics ( PK ) MVT-5873 determine Group .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Inclusion Criteria 1 . Signed , inform consent 2 . Age 18 year 3 . Histologically confirm , locallyadvanced metastatic pancreatic ductal adenocarcinoma ( PDAC ) CA199 positive malignancy 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 KPS 100 % 80 % 5 . Adequate hematologic , hepatic , renal function Exclusion Criteria 1 . Brain metastasis unless previously treat well control least 3 month 2 . Other known active cancer ( ) likely require treatment next two ( 2 ) year 3 . Active , uncontrolled bacterial , viral , fungal infection ( ) require systemic therapy 4 . Fewer 28 day prior anticancer therapy include chemotherapy , hormonal , investigational , and/or biological therapy irradiation except prostate cancer hormonal therapy , treatment MVT5873 MVT2163 . 5 . Major surgery diagnostic surgery within 28 day Study Day 1 6 . History anaphylactic reaction human , humanize , antibody 7 . Pregnant currently breastfeed 8 . Known HIVpositive Hepatitis C 9 . Psychiatric illness/social situation would interfere compliance study requirement 10 . Significant cardiovascular risk include , limited , recent ( within 4 week ) coronary stenting myocardial infarction within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>CA19-9 Positive Malignancies</keyword>
</DOC>